HEPATOCELLULAR CARCINOMA DRUGS MARKET ANALYSIS
Competitive Analysis
The manufactures are focused on strategic collaborations to jointly develop and commercialize immunotherapies indicated to treat broad range of tumors. For instance, in 2014, Bristol-Myers Squibb Company and Ono Pharmaceutical Co., Ltd. signed a strategic collaboration agreement to jointly develop and commercialize multiple immunotherapies as single agents and combination therapies with Opdivo, to help address the unmet medical needs of patients with cancer in Japan, South Korea and Taiwan. Also, in 2015, Novartis Pharmaceuticals initiated the Phase 2 trials to compare the safety and efficacy for dovitinib and sorafenib in adult patients with advanced hepatocellular carcinoma.
Key players operating in the global hepatocellular carcinoma drugs market include Novartis Pharmaceuticals, Bayer AG, Merck & Co., Inc., Bristol-Myers Squibb Company, AbbVie Inc., Johnson & Johnson, Celgen Corporation, Amgen Inc., Teva Pharmaceutical Industries Ltd., Pfizer Inc., and Takeda Pharmaceutical Co. Ltd.
Hepatocellular Carcinoma Drugs Market Report Snapshots
Need a Custom Report?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize NowWant to Buy a Report but have a Limited Budget?
We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail
Request Discount
Credibility and Certifications
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients